Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice
Background Regorafenib is an orally administered multikinase inhibitor that has been approved for patients with chemotherapy-refractory metastatic colorectal cancer (mCRC). Even though regorafenib significantly improved survival in two international phase 3 trials (CORRECT and CONCUR), a high rate o...
Main Authors: | Fabien Calcagno, Sabrina Lenoble, Zaher Lakkis, Thierry Nguyen, Samuel Limat, Christophe Borg, Marine Jary, Stefano Kim, Virginie Nerich |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2016-01-01
|
Series: | Clinical Medicine Insights: Oncology |
Online Access: | https://doi.org/10.4137/CMO.S38335 |
Similar Items
-
Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice
by: Fabien Calcagno, et al.
Published: (2016-07-01) -
The role of regorafenib in the treatment of metastatic colorectal cancer
by: A A Tryakin
Published: (2016-06-01) -
Monitoring levels of circulating cell‐free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment
by: Brice Pastor, et al.
Published: (2021-09-01) -
Practical considerations in the use of regorafenib in metastatic colorectal cancer
by: Fotios Loupakis, et al.
Published: (2020-10-01) -
Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib
by: Barbara Melosky
Published: (2016-01-01)